

Saudi Arabia In-vitro Diagnostics Market Assessment, By Product Type [Instruments, Reagents and Consumables, Data Management Software], By Techniques [Immunodiagnosics, Clinical Chemistry, Molecular Diagnostics, Microbiology, Hematology, Coagulation and Hemostasis, Urinalysis, Others], By Settings [Laboratories, Point-of-Care], By Application [Infectious Diseases, Diabetes, Drug Testing/ Pharmacogenomics, Autoimmune Diseases, Cardiology, Oncology, HIV/AIDS, Nephrology, Gastroenterology, Others], By End-user [Clinical Laboratories, Hospitals, Point-of-care testing centers, Others], Opportunities and Forecast, 2016-2030F

Market Report | 2024-04-19 | 155 pages | Market Xcel - Markets and Data

AVAILABLE LICENSES:

- Single User License \$3300.00
- Muti-User/Corporate Licence \$4500.00
- Custom Research License \$7000.00

Report description:

Saudi Arabia in-vitro diagnostics market is projected to witness a CAGR of 6.01% during the forecast period 2023-2030, growing from USD 2.78 billion in 2022 to USD 4.44 billion in 2030. The market is expected to maintain a strong pace of expansion in the coming years owing to the attempts to strengthen the healthcare sector in the region.

In-vitro diagnostics (IVD) refers to medical equipment and reagents designed to conduct diagnostic tests on biological samples like blood, urine, and tissues. These tests diagnose and analyze infectious diseases, autoimmune disorders, and various medical conditions. Additionally, they are utilized to assess adjustments in drug therapy at regular intervals.

The Saudi Arabia in vitro diagnostics market has experienced significant growth in recent years, propelled by factors such as a rising awareness of the importance of early disease detection, increasing prevalence of chronic and infectious diseases, and

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

advancements in medical technology. Furthermore, the government and corporate attempts to improve and expand the healthcare system in the country are also propelling the market growth.

Additionally, the growing elderly population and changing lifestyle patterns have contributed to the increased demand for accurate and swift diagnostic solutions. The segments within the IVD market, including clinical chemistry, immunoassays, molecular diagnostics, hematology, and point-of-care testing, have witnessed remarkable growth. The demand for more sophisticated and personalized healthcare solutions has boosted the adoption of molecular diagnostics and genetic testing, allowing for early identification of genetic predispositions and personalized treatment plans.

Market players, ranging from multinational corporations to local manufacturers, are actively engaged in product innovation and development to meet the evolving healthcare needs of the population. Regulatory authorities, such as the Saudi Food and Drug Authority (SFDA), play a pivotal role in ensuring the quality and safety of IVD products entering the market.

In October 2023, Anbio Biotechnology showcased its debut at AACC Middle East 2023 held in Dubai. This debut marked Anbio's official launch of in vitro diagnostic (IVD) products in the Middle East market. The launch showcased Anbio's commitment for delivering effective and affordable laboratory and point-of-care in-vitro diagnostic solutions in the Middle East region and globally.

Advancement in Immunodiagnostics

In Saudi Arabia, the field of immunodiagnostics has witnessed remarkable advancements in the in vitro diagnostics market. The convergence of innovative technologies and a growing emphasis on healthcare has fueled this progress. The integration of automated systems, such as chemiluminescence and ELISA platforms, has enhanced the efficiency and accuracy of immunodiagnostic tests, allowing for rapid and reliable detection of various diseases.

Moreover, the utilization of novel biomarkers and monoclonal antibodies has expanded diagnostic capabilities, enabling early disease identification and personalized treatment approaches. The collaboration between research institutions, healthcare providers, and industry players has facilitated the development of indigenous immunodiagnostic solutions tailored to regional healthcare needs. As a result, Saudi Arabia stands at the forefront of immunodiagnostics innovation and has been contributing significantly to improved patient outcomes and public health management.

In December 2022, bioMérieux revealed that VIDAS KUBE, the advanced automated immunoassay system designed for the VIDAS range, had received the CE-marking. VIDAS has revolutionized immunoassays, granting laboratories widespread entry to a straightforward, automated, and resilient technology, ensuring swift and dependable outcomes. VIDAS, with its all-in-one kit adopting a single-test approach, is presently employed in over 160 nations across 25,000 laboratories. It continues to stand as one of the foremost immunoassay systems utilized in clinical laboratories globally.

High Prevalence of Chronic Diseases Drive Demand for IVD

The significant prevalence of chronic conditions such as diabetes, cancer, cardiovascular diseases, and infectious diseases is projected to play a vital role in propelling the in-vitro diagnostics market in Saudi Arabia. In-vitro diagnostic techniques are crucial for diagnosing and monitoring these ailments. This escalating burden of chronic diseases in Saudi Arabia is poised to drive the demand for in-vitro diagnostics products in the country, consequently fostering growth in the Saudi Arabia in-vitro diagnostics market. Moreover, the report by the International Diabetes Federation (IDF) predicts that the diabetes burden in Saudi Arabia will surge from 4.3 million in 2021 to 7.5 million by 2045.

For instance, In September 2023, according to a factsheet by WHO, Noncommunicable diseases (NCDs) are responsible for killing 41 million people each year, equivalent to 74% of all deaths globally. Around 17 million people die from an NCD before the age of 70 years; 86% of these premature deaths occur in low- and middle-income countries. Cardiovascular diseases (CVDs) account for most NCD deaths, (17.9 million people annually), followed by cancers (9.3 million), chronic respiratory diseases (4.1 million), and diabetes (2.0 million).

Amplifying Advancement through Strategic Collaboration among Key Players

The progress in Saudi Arabia in vitro diagnostics market requires a concerted effort of strategic collaboration among key stakeholders. By fostering partnerships between healthcare institutions, research organizations, regulatory bodies, and industry leaders, the IVD sector can unlock new avenues of advancement. Collaborative initiatives can facilitate the sharing of expertise, resources, and data, expediting the development and adoption of innovative diagnostic technologies. These collaborations encompass joint research projects, knowledge-sharing symposiums, and streamlined regulatory processes. Through such collective endeavors, Saudi Arabia can bolster its local IVD capabilities, improve healthcare outcomes, and contribute to global

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

advancements in diagnostics. The collaborative approach will address healthcare challenges effectively and stimulate economic growth and innovation in the IVD market, ultimately benefiting both the nation's health and its position in the global medical landscape.

In April 2023, Oxford Nanopore Technologies plc joined forces with bioMérieux SA to improve worldwide health results by investigating specific avenues for introducing nanopore sequencing to the market of infectious disease diagnostics.

Dominance of Immunodiagnostics and Growth in Molecular Diagnostics

The immunodiagnostics segment is anticipated to be the leading segment during the assessment period in the market with 35.14% of value share while the molecular diagnostics segment is expected to grow at a significantly higher pace with a CAGR of 7.19% during the forecast period. The rise in infectious and immunological diseases in the region is resulting in higher demand for the immunodiagnostics segment while consanguineous marriage trends among locals in Saudi Arabia is leading to the high prevalence of genetic anomalies is driving the demand for molecular diagnostics.

Saudi Arabia Heavily Rely on Imports for IVD Products

Saudi Arabia is a fast-developing nation, but it relies heavily on imports from European, Asian, and American nations for its healthcare requirements. More than 70% of the healthcare requirements of Saudi Arabia are fulfilled through imports only. As per the recent report by the Gulf Cooperation Council (GCC), in GCC nations the healthcare sector can be segmented into medical devices accounting for 70% of revenues, followed by In-vitro diagnostic (IVD), accounting for 19% of revenues, and medical imaging accounting for 11%. Domestic manufacturing accounts for less than 20% of the market revenues Council (GCC) and is still in its early stages of development. This poses an immense opportunity for manufacturers to thrive in setting up domestic production units in the country. Saudi Arabia's government launched 'Vision 2030' initiative in 2016 to improve access to healthcare, modernize facilities and equipment, and enhance the role of private sector investment in the healthcare sector. In line with the 'Vision 2030' initiative, there are immense opportunities for market players in the healthcare sector to expand alongside the in-vitro diagnostics market.

Impact of COVID-19

During the initial stages of the pandemic, Saudi Arabia enforced a lockdown, halted international trade, and imposed travel restrictions, resulting in a reduction in medical diagnoses in the first half of 2020. Several research studies were conducted to shed light on the pandemic's impact on the analyzed market. For example, a research paper titled "COVID-19 pandemic outbreak in Saudi Arabia: An overview," published in July 2020, highlighted that extensive measures like global shutdowns, quarantines, and lockdowns had been implemented to curb the spread of the COVID-19 virus. Consequently, these measures initially impeded market growth. Nevertheless, as the number of COVID-19 patients increased and the demand for diagnostics rose in centers, clinics, hospitals, and mobile units, a significant demand for in vitro diagnostics emerged in Saudi Arabia. Given the substantial opportunities in the region, major stakeholders have devised strategies to exploit the potential. In June 2021, G42 Healthcare and Seegene Inc. entered a Memorandum of Understanding (MoU) to deliver fully equipped mobile diagnostic and testing laboratories across the Middle East and North Africa, including Saudi Arabia. Consequently, the market exhibited growth during the pandemic.

Future Market Scenario (2023 – 2030F)

- Growing chronic disease cases and genetic anomalies are majorly driving the demand in the in-vitro diagnostics market.
- Rising technological advancements in diagnostic techniques and instruments are contributing to market growth.
- Molecular diagnostics segment is the fastest-growing segment in the in-vitro diagnostics market due to the growing applications of genetic studies and the high rate of genetic diseases in Saudi Arabia.
- Point-of-care segment is expected to grow at a faster pace due to the growing demand for personalized treatment and increasing disposable income in Saudi Arabia.

Key Players Landscape and Outlook

Key participants in the Saudi Arabia in-vitro diagnostics market include F. Hoffmann-La Roche AG, Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Thermo Fisher Scientific Inc., BD, as these companies compete to outperform one another in terms of patient compliance, safety, accuracy, and unique features. The market prognosis remains positive, owing to increased demand for in-vitro diagnostics procedures. In-vitro diagnostics manufacturers are actively involved in designing innovative solutions. Industry tactics like partnerships and collaborations are helping the players to grow.

In November 2023, KDX Diagnostics Inc. announced distribution partnerships in Europe and the Middle East and stated that its

collaboration with top Middle Eastern and European distributors is evidence of its commitment to growing its worldwide footprint. KDX Diagnostics is ready to expand its reach to patients and healthcare providers throughout Europe and the Middle East. The URO17 Bladder Cancer Test has already made great progress in improving the bladder cancer diagnosis procedure in the United States.

Table of Contents:

- 1. Research Methodology
- 2. Project Scope & Definitions
- 3. Executive Summary
- 4. Saudi Arabia In-vitro Diagnostics Market Outlook, 2016-2030F
 - 4.1. Market Size & Forecast
 - 4.1.1. By Value
 - 4.2. By Product Type
 - 4.2.1. Instruments
 - 4.2.2. Reagents and Consumables
 - 4.2.3. Data Management Software
 - 4.3. By Techniques
 - 4.3.1. Immunodiagnostics
 - 4.3.2. Clinical Chemistry
 - 4.3.3. Molecular Diagnostics
 - 4.3.4. Microbiology
 - 4.3.5. Haematology
 - 4.3.6. Coagulation and Haemostasis
 - 4.3.7. Urinalysis
 - 4.3.8. Others
 - 4.4. By Settings
 - 4.4.1. Laboratories
 - 4.4.2. Point-of-Care
 - 4.5. By Application
 - 4.5.1. Ophthalmology
 - 4.5.2. Infectious Diseases
 - 4.5.3. Diabetes
 - 4.5.4. Drug Testing/ Pharmacogenomics
 - 4.5.5. Autoimmune Diseases
 - 4.5.6. Cardiology
 - 4.5.7. Oncology
 - 4.5.8. HIV/AIDS
 - 4.5.9. Nephrology
 - 4.5.10. Gastroenterology
 - 4.5.11. Others
 - 4.6. By End-user
 - 4.6.1. Clinical Laboratories
 - 4.6.2. Hospitals
 - 4.6.3. Point-of-care testing centres
 - 4.6.4. Others
 - 4.7. By Region
 - 4.7.1. Central

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 4.7.2.□Western
- 4.7.3.□Northern
- 4.7.4.□Eastern
- 4.7.5.□Southern
- 5.□Market Mapping, 2022
- 5.1.□By Product Type
- 5.2.□By Techniques
- 5.3.□By Settings
- 5.4.□By Application
- 5.5.□By End-user
- 5.6.□By Region
- 6.□Macro Environment and Industry Structure
- 6.1.□Demand Supply Analysis
- 6.2.□Import Export Analysis
- 6.3.□Value Chain Analysis
- 6.4.□PESTEL Analysis
- 6.4.1.□Political Factors
- 6.4.2.□Economic System
- 6.4.3.□Social Implications
- 6.4.4.□Technological Advancements
- 6.4.5.□Environmental Impacts
- 6.4.6.□Legal Compliances and Regulatory Policies (Statutory Bodies Included)
- 6.5.□Porter's Five Forces Analysis
- 6.5.1.□Supplier Power
- 6.5.2.□Buyer Power
- 6.5.3.□Substitution Threat
- 6.5.4.□Threat from New Entrant
- 6.5.5.□Competitive Rivalry
- 7.□Market Dynamics
- 7.1.□Growth Drivers
- 7.2.□Growth Inhibitors (Challenges and Restraints)
- 8.□Regulatory Framework and Innovation
- 8.1.□Clinical Trial
- 8.2.□Patent Landscape
- 8.3.□Regulatory Approvals
- 8.4.□Innovations/Emerging Technologies
- 9.□Key Players Landscape
- 9.1.□Competition Matrix of Top Five Market Leaders
- 9.2.□Market Revenue Analysis of Top Five Market Leaders (in %, 2022)
- 9.3.□Mergers and Acquisitions/Joint Ventures (If Applicable)
- 9.4.□SWOT Analysis (For Five Market Players)
- 10.□Case Studies
- 11.□Key Players Outlook
- 11.1.□F. Hoffmann-La Roche AG
- 11.1.1.□Company Details
- 11.1.2.□Key Management Personnel
- 11.1.3.□Products & Services

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.1.4. □Financials (As reported)
- 11.1.5. □Key Market Focus & Geographical Presence
- 11.1.6. □Recent Developments
- 11.2. □Abbott Laboratories
- 11.3. □Danaher Corporation
- 11.4. □Siemens Healthineers AG
- 11.5. □Thermo Fisher Scientific Inc
- 11.6. □BD (Becton, Dickinson, and Company)
- 11.7. □Nihon Kohden Corporation
- 11.8. □BioMerieux SA
- 11.9. □Bio-Rad Laboratories, Inc
- 11.10. □Agilent Technologies, Inc
- 11.11. □Qiagen NV

*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

- 12. □Strategic Recommendations
- 13. □About Us & Disclaimer

Saudi Arabia In-vitro Diagnostics Market Assessment, By Product Type [Instruments, Reagents and Consumables, Data Management Software], By Techniques [Immunodiagnosics, Clinical Chemistry, Molecular Diagnostics, Microbiology, Hematology, Coagulation and Hemostasis, Urinalysis, Others], By Settings [Laboratories, Point-of-Care], By Application [Infectious Diseases, Diabetes, Drug Testing/ Pharmacogenomics, Autoimmune Diseases, Cardiology, Oncology, HIV/AIDS, Nephrology, Gastroenterology, Others], By End-user [Clinical Laboratories, Hospitals, Point-of-care testing centers, Others], Opportunities and Forecast, 2016-2030F

Market Report | 2024-04-19 | 155 pages | Market Xcel - Markets and Data

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$3300.00
	Muti-User/Corporate Licence	\$4500.00
	Custom Research License	\$7000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-06"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com